Image Source: AsiaOne
Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous BoosterGlobeNewswireJune 27, 2022SCB-2019 (CpG 1018/Alum) as a third dose exhibited a 19-fold boost in neutralizing antibodies against Omicron BA.2 variant among baseline seronegative participantsNew positive data adds to growing body of evidence supporting potential use of SCB-2019 (CpG 1018/Alum) as a universal COVID-19 booster vaccineSHANGHAI, China, June 27, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd.
Source: AsiaOne